Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658596 | 1.00 | LMNA (0.65) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL18292499 | 0.88 | LMNA (0.65) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2650986 | 0.83 | GCK (0.61) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2650987 | 0.83 | GCK (0.61) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2658755 | 0.83 | ALDH1A1 (0.47) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2658757 | 0.83 | ALDH1A1 (0.47) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2650995 | 0.78 | MAPT (0.45) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2651643 | 0.78 | MAPT (0.45) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2651000 | 0.78 | MAPT (0.45) | LMNAMAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2651647 | 0.78 | MAPT (0.45) | LMNAMAPTKMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | LMNA 4157/4885MAPT 1785/4885KMT2A 3903/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | LMNA 4250/4885MAPT 1611/4885KMT2A 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.